Last week we received Professor Sarah E. Coupland from Liverpool, as the Visiting Professor of InFLAMES. It has been delightful to watch her amazing lectures, in addition to a profound meditation on how to strive for a successful academic career with all the challenges that come along on all fronts, and still maintaining a noble meaningful life full of personal achievements. From a modest early career stage until coming to prominence as the president of different funding institutions and scientific societies, Sarah shared the most important tips and tricks we need to bear in mind for academic success, with the most important aspect being persistence.
Sarah had a very busy schedule where she also managed to provide with excellent scientific lectures regarding rare tumors that hide the knowledge gaps of cancer immune escape. From her lectures, we could better grasp how difficult is to factor the most refractory cancer type to current immunotherapies, uveal melanoma. Despite the difficulties for developing proper in vivo models that would accelerate preclinical research in uveal melanoma, Sarah’s group advanced in establishing important scientific grounds, mostly given to the foundation of what is considered today one of the largest and successful biobanks for these rare intraocular tumors.
It has been a good month for Figueiredo’s group (MIORG) as one of the contributors of the InFLAMES flagship: a significant grant from the Jane and Aatos Erkko Foundation was just awarded. This funding opportunity will support our Academy of Finland project in the development of new adjuvant treatments to improve current immunotherapies for both cutaneous and ocular melanomas, where Sarah is an active collaborator.
Carlos De Figueiredo - InFlames
Sarah had a very busy schedule where she also managed to provide with excellent scientific lectures regarding rare tumors that hide the knowledge gaps of cancer immune escape. From her lectures, we could better grasp how difficult is to factor the most refractory cancer type to current immunotherapies, uveal melanoma. Despite the difficulties for developing proper in vivo models that would accelerate preclinical research in uveal melanoma, Sarah’s group advanced in establishing important scientific grounds, mostly given to the foundation of what is considered today one of the largest and successful biobanks for these rare intraocular tumors.
It has been a good month for Figueiredo’s group (MIORG) as one of the contributors of the InFLAMES flagship: a significant grant from the Jane and Aatos Erkko Foundation was just awarded. This funding opportunity will support our Academy of Finland project in the development of new adjuvant treatments to improve current immunotherapies for both cutaneous and ocular melanomas, where Sarah is an active collaborator.
Carlos De Figueiredo - InFlames
